This Biopharmaceutical CMO market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The biopharmaceutical CMO market size has grown rapidly in recent years. It will grow from $24.81 billion in 2024 to $28.09 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, globalization, rise in healthcare expenditure, regulatory support, increased research funding.
The biopharmaceutical CMO market size is expected to see rapid growth in the next few years. It will grow to $48.04 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rise in telehealth and remote trials, global health initiatives, rise in disposable income, global health initiatives. Major trends in the forecast period include advanced therapies dominance, digitalization and industry 4.0, continuous manufacturing, sustainability and green practices.
An increase in the strength of venture capital investments in the life science sector is expected to fuel the growth of the biopharmaceutical Contract Manufacturing Organization (CMO) market. The life sciences sector includes businesses and organizations involved in research and development related to living organisms. The strength of venture capital investments indicates how effectively a model, test, or system can operate when parameters or assumptions are changed. For example, in May 2024, the Department of Health and Social Care, a UK-based government agency, reported that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue in 2021/22, representing 43% of the entire life sciences industry. Additionally, in 2024, AusBiotech, an organization based in Australia, stated that the biotechnology sector reached USD 5.66 billion (AU$8.67 billion) in total revenues by 2021, with a growth rate of 4.4%. This significant investment is anticipated to boost the manufacturing of biopharmaceuticals, contributing to the growth of the biopharmaceutical CMO market.
The increasing burden of chronic diseases is poised to fuel the growth of the biopharmaceutical CMO market. Chronic diseases, characterized by prolonged health conditions requiring ongoing medical management, represent a significant global health challenge. Biopharmaceutical CMOs play a crucial role in addressing chronic diseases by expediting drug development, ensuring cost-effective production, and maintaining high-quality standards. According to the National Library of Medicine, the US population aged 50 and older is projected to increase by 61.11% from 137.25 million in 2020 to 221.13 million in 2050, with the number of individuals with at least one chronic disease estimated to rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. This growing burden of chronic diseases is a key driver for the biopharmaceutical CMO market.
Technological advancement emerges as a prominent trend in the biopharmaceutical CMO market. Major companies in this sector are focusing on advancing technologies through research and development, leveraging the Internet of Things (IoT). The IoT involves the application of networked sensors and actuators for monitoring and controlling manufacturing environments. The vast amount of data generated by IoT-enabled systems can be analyzed to enhance production efficiency, automate tasks, and enable adaptable manufacturing. In February 2022, M2Cloud and Thales collaborated to develop an IoT-based LTE monitoring system for biopharmaceutical monitoring. This system facilitates real-time monitoring of freezers, refrigerated warehouses, and delivery boxes, ensuring temperature and position information verification. Technological advancements like these contribute to the safety and efficiency of biopharmaceutical product management, driving growth in the biopharmaceutical CMO market.
Leading companies in the biopharmaceutical CMO market are increasingly pursuing strategic partnerships to create innovative biopharmaceutical products. These collaborations enable biopharmaceutical CMO firms to pool resources and expertise, enhance research and development capabilities, broaden their market presence, and speed up commercialization. This approach ultimately fosters innovation and growth within the biopharmaceutical CMO sector. For example, in May 2024, BioConnection, a contract manufacturing company based in the Netherlands, joined forces with AGC Biologics, a contract development and manufacturing organization in the United States. Through this partnership, they aim to provide a streamlined, all-encompassing solution for biopharmaceutical development and manufacturing, thereby expediting timelines and simplifying processes for drug developers.
In May 2023, WACKER, a chemical company based in Germany, acquired ADL BioPharma for an undisclosed amount. This acquisition aims to strengthen WACKER's biotechnology operations and expand its fermentation capacities for sustainably produced food ingredients, aligning with its future growth goals. ADL BioPharma is a contract manufacturing company located in Spain that specializes in the development and production of high-quality fermentation products.
Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG.
Biopharmaceutical CMO (Contract Manufacturing Organization) is a business that provides manufacturing services, capable of producing small quantities for preclinical research and development, as well as larger quantities required for clinical trials and commercialization. Biopharmaceutical CMOs play a crucial role in reducing overall operational risk and time to market for pharmaceutical products.
The main types of biopharmaceutical CMO products include biologics and biosimilars. Biologics encompass a diverse range of products derived from human, animal, or microbial sources, serving as medications. These substances are produced from living organisms or contain components thereof. Examples of biologic medications include vaccines, blood products, cells, allergens, genes, tissues, and recombinant proteins. Biopharmaceutical CMO products can be sourced from various origins, including mammalian and non-mammalian sources. Biopharmaceutical CMO services cover a spectrum of activities such as manufacturing, fill and finish operations, analytical and quality control studies, and packaging. These services are crucial for pharmaceutical companies looking to outsource certain aspects of their production processes, allowing them to focus on research, development, and commercialization efforts.
The biopharmaceutical CMO market research report is one of a series of new reports that provides biopharmaceutical CMO market statistics, including biopharmaceutical CMO industry global market size, regional shares, competitors with a biopharmaceutical CMO market share, detailed biopharmaceutical CMO market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical CMO industry. This biopharmaceutical CMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical CMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the biopharmaceutical CMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The biopharmaceutical CMO market includes revenues earned by entities by process development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The biopharmaceutical CMO market size has grown rapidly in recent years. It will grow from $24.81 billion in 2024 to $28.09 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, globalization, rise in healthcare expenditure, regulatory support, increased research funding.
The biopharmaceutical CMO market size is expected to see rapid growth in the next few years. It will grow to $48.04 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rise in telehealth and remote trials, global health initiatives, rise in disposable income, global health initiatives. Major trends in the forecast period include advanced therapies dominance, digitalization and industry 4.0, continuous manufacturing, sustainability and green practices.
An increase in the strength of venture capital investments in the life science sector is expected to fuel the growth of the biopharmaceutical Contract Manufacturing Organization (CMO) market. The life sciences sector includes businesses and organizations involved in research and development related to living organisms. The strength of venture capital investments indicates how effectively a model, test, or system can operate when parameters or assumptions are changed. For example, in May 2024, the Department of Health and Social Care, a UK-based government agency, reported that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue in 2021/22, representing 43% of the entire life sciences industry. Additionally, in 2024, AusBiotech, an organization based in Australia, stated that the biotechnology sector reached USD 5.66 billion (AU$8.67 billion) in total revenues by 2021, with a growth rate of 4.4%. This significant investment is anticipated to boost the manufacturing of biopharmaceuticals, contributing to the growth of the biopharmaceutical CMO market.
The increasing burden of chronic diseases is poised to fuel the growth of the biopharmaceutical CMO market. Chronic diseases, characterized by prolonged health conditions requiring ongoing medical management, represent a significant global health challenge. Biopharmaceutical CMOs play a crucial role in addressing chronic diseases by expediting drug development, ensuring cost-effective production, and maintaining high-quality standards. According to the National Library of Medicine, the US population aged 50 and older is projected to increase by 61.11% from 137.25 million in 2020 to 221.13 million in 2050, with the number of individuals with at least one chronic disease estimated to rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. This growing burden of chronic diseases is a key driver for the biopharmaceutical CMO market.
Technological advancement emerges as a prominent trend in the biopharmaceutical CMO market. Major companies in this sector are focusing on advancing technologies through research and development, leveraging the Internet of Things (IoT). The IoT involves the application of networked sensors and actuators for monitoring and controlling manufacturing environments. The vast amount of data generated by IoT-enabled systems can be analyzed to enhance production efficiency, automate tasks, and enable adaptable manufacturing. In February 2022, M2Cloud and Thales collaborated to develop an IoT-based LTE monitoring system for biopharmaceutical monitoring. This system facilitates real-time monitoring of freezers, refrigerated warehouses, and delivery boxes, ensuring temperature and position information verification. Technological advancements like these contribute to the safety and efficiency of biopharmaceutical product management, driving growth in the biopharmaceutical CMO market.
Leading companies in the biopharmaceutical CMO market are increasingly pursuing strategic partnerships to create innovative biopharmaceutical products. These collaborations enable biopharmaceutical CMO firms to pool resources and expertise, enhance research and development capabilities, broaden their market presence, and speed up commercialization. This approach ultimately fosters innovation and growth within the biopharmaceutical CMO sector. For example, in May 2024, BioConnection, a contract manufacturing company based in the Netherlands, joined forces with AGC Biologics, a contract development and manufacturing organization in the United States. Through this partnership, they aim to provide a streamlined, all-encompassing solution for biopharmaceutical development and manufacturing, thereby expediting timelines and simplifying processes for drug developers.
In May 2023, WACKER, a chemical company based in Germany, acquired ADL BioPharma for an undisclosed amount. This acquisition aims to strengthen WACKER's biotechnology operations and expand its fermentation capacities for sustainably produced food ingredients, aligning with its future growth goals. ADL BioPharma is a contract manufacturing company located in Spain that specializes in the development and production of high-quality fermentation products.
Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG.
Biopharmaceutical CMO (Contract Manufacturing Organization) is a business that provides manufacturing services, capable of producing small quantities for preclinical research and development, as well as larger quantities required for clinical trials and commercialization. Biopharmaceutical CMOs play a crucial role in reducing overall operational risk and time to market for pharmaceutical products.
The main types of biopharmaceutical CMO products include biologics and biosimilars. Biologics encompass a diverse range of products derived from human, animal, or microbial sources, serving as medications. These substances are produced from living organisms or contain components thereof. Examples of biologic medications include vaccines, blood products, cells, allergens, genes, tissues, and recombinant proteins. Biopharmaceutical CMO products can be sourced from various origins, including mammalian and non-mammalian sources. Biopharmaceutical CMO services cover a spectrum of activities such as manufacturing, fill and finish operations, analytical and quality control studies, and packaging. These services are crucial for pharmaceutical companies looking to outsource certain aspects of their production processes, allowing them to focus on research, development, and commercialization efforts.
The biopharmaceutical CMO market research report is one of a series of new reports that provides biopharmaceutical CMO market statistics, including biopharmaceutical CMO industry global market size, regional shares, competitors with a biopharmaceutical CMO market share, detailed biopharmaceutical CMO market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical CMO industry. This biopharmaceutical CMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical CMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the biopharmaceutical CMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The biopharmaceutical CMO market includes revenues earned by entities by process development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Biopharmaceutical CMO Market Characteristics3. Biopharmaceutical CMO Market Trends and Strategies4. Biopharmaceutical CMO Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Biopharmaceutical CMO Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Biopharmaceutical CMO Market34. Recent Developments in the Biopharmaceutical CMO Market
5. Global Biopharmaceutical CMO Growth Analysis and Strategic Analysis Framework
6. Biopharmaceutical CMO Market Segmentation
7. Biopharmaceutical CMO Market Regional and Country Analysis
8. Asia-Pacific Biopharmaceutical CMO Market
9. China Biopharmaceutical CMO Market
10. India Biopharmaceutical CMO Market
11. Japan Biopharmaceutical CMO Market
12. Australia Biopharmaceutical CMO Market
13. Indonesia Biopharmaceutical CMO Market
14. South Korea Biopharmaceutical CMO Market
15. Western Europe Biopharmaceutical CMO Market
16. UK Biopharmaceutical CMO Market
17. Germany Biopharmaceutical CMO Market
18. France Biopharmaceutical CMO Market
19. Italy Biopharmaceutical CMO Market
20. Spain Biopharmaceutical CMO Market
21. Eastern Europe Biopharmaceutical CMO Market
22. Russia Biopharmaceutical CMO Market
23. North America Biopharmaceutical CMO Market
24. USA Biopharmaceutical CMO Market
25. Canada Biopharmaceutical CMO Market
26. South America Biopharmaceutical CMO Market
27. Brazil Biopharmaceutical CMO Market
28. Middle East Biopharmaceutical CMO Market
29. Africa Biopharmaceutical CMO Market
30. Biopharmaceutical CMO Market Competitive Landscape and Company Profiles
31. Biopharmaceutical CMO Market Other Major and Innovative Companies
35. Biopharmaceutical CMO Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Biopharmaceutical CMO Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on biopharmaceutical cmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biopharmaceutical cmo? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biopharmaceutical cmo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Biologics; Biosimilars2) By Source: Mammalian; Non-Mammalian
3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging
Subsegments:
1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones
Key Companies Mentioned: Lonza Group AG; Fujifilm Diosynth Biotechnologies USA Inc.; Thermo Fisher Scientific Inc.; Samsung Biologics; WuXi AppTec
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Biopharmaceutical CMO market report include:- Lonza Group AG
- Fujifilm Diosynth Biotechnologies USA Inc.
- Thermo Fisher Scientific Inc.
- Samsung Biologics
- WuXi AppTec
- Catalent, Inc.
- Rentschler Biopharma SE
- Boehringer Ingelheim
- Recipharm AB
- AGC Biologics
- CMC Biologics
- KBI Biopharma
- Vetter Pharma International GmbH
- Emergent BioSolutions Inc.
- Aenova Group
- Synlogic, Inc.
- MedImmune (AstraZeneca)
- BioLife Sciences
- Bio-Xcellence (Boehringer Ingelheim)
- AbbVie Contract Manufacturing
- PCI Pharma Services
- AltheaDx
- Daxor Corporation
- Genomatica, Inc.
- Astellas Pharma
- Juno Therapeutics (Celgene)
- Medpace
- Celerion
- Evonik Industries AG
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | January 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 28.09 Billion |
Forecasted Market Value ( USD | $ 48.04 Billion |
Compound Annual Growth Rate | 14.4% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |